524212 Stock Overview
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Wanbury Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹158.10 |
| 52 Week High | ₹177.40 |
| 52 Week Low | ₹41.20 |
| Beta | 0.40 |
| 1 Month Change | 11.61% |
| 3 Month Change | 10.56% |
| 1 Year Change | 263.28% |
| 3 Year Change | 51.00% |
| 5 Year Change | 665.62% |
| Change since IPO | -15.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524212 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 5.8% | -1.4% | -1.6% |
| 1Y | 263.3% | 53.7% | 45.0% |
Return vs Industry: 524212 exceeded the Indian Pharmaceuticals industry which returned 53.7% over the past year.
Return vs Market: 524212 exceeded the Indian Market which returned 45% over the past year.
Price Volatility
| 524212 volatility | |
|---|---|
| 524212 Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 524212 has not had significant price volatility in the past 3 months.
Volatility Over Time: 524212's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 1,582 | Mohan Rayana | www.wanbury.com |
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas.
Wanbury Limited Fundamentals Summary
| 524212 fundamental statistics | |
|---|---|
| Market cap | ₹5.18b |
| Earnings (TTM) | ₹233.39m |
| Revenue (TTM) | ₹5.69b |
22.2x
P/E Ratio0.9x
P/S RatioIs 524212 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524212 income statement (TTM) | |
|---|---|
| Revenue | ₹5.69b |
| Cost of Revenue | ₹3.12b |
| Gross Profit | ₹2.57b |
| Other Expenses | ₹2.34b |
| Earnings | ₹233.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.13 |
| Gross Margin | 45.13% |
| Net Profit Margin | 4.10% |
| Debt/Equity Ratio | -509.4% |
How did 524212 perform over the long term?
See historical performance and comparison